NZ553058A - Composition and method for raising blood glucose level - Google Patents

Composition and method for raising blood glucose level

Info

Publication number: NZ553058A
Authority: NZ; New Zealand
Prior art keywords: composition; glucose; dispenser; concentration; individual
Prior art date: 2006-10-06

Application number

NZ55305807A

Other languages

English (en)

Inventor

Anna E Gluskin

Muhammad Waseem T Qazi

Original Assignee

Generex Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-06

Filing date

2007-02-07

Publication date

2008-11-28

2006-10-06 Priority claimed from CA002562821A external-priority patent/CA2562821A1/en

2007-02-07 Application filed by Generex Pharm Inc filed Critical Generex Pharm Inc

2008-11-28 Publication of NZ553058A publication Critical patent/NZ553058A/en

Links

WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 236
239000008103 glucose Substances 0.000 title claims abstract description 236
239000000203 mixture Substances 0.000 title claims abstract description 171
239000008280 blood Substances 0.000 title claims abstract description 64
210000004369 blood Anatomy 0.000 title claims abstract description 64
238000000034 method Methods 0.000 title description 18
238000010521 absorption reaction Methods 0.000 claims abstract description 31
239000003623 enhancer Substances 0.000 claims abstract description 26
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 24
235000011187 glycerol Nutrition 0.000 claims abstract description 12
-1 polyglycerin Chemical compound 0.000 claims abstract description 10
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 8
229910052783 alkali metal Inorganic materials 0.000 claims abstract description 7
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims abstract description 6
210000002200 mouth mucosa Anatomy 0.000 claims abstract description 6
150000003839 salts Chemical class 0.000 claims abstract description 6
NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 5
NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 5
229940041616 menthol Drugs 0.000 claims abstract description 5
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 4
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 4
239000004471 Glycine Substances 0.000 claims abstract description 4
239000008186 active pharmaceutical agent Substances 0.000 claims abstract description 4
239000003937 drug carrier Substances 0.000 claims abstract description 4
229920002674 hyaluronan Polymers 0.000 claims abstract description 4
229960003160 hyaluronic acid Drugs 0.000 claims abstract description 4
239000000787 lecithin Substances 0.000 claims abstract description 4
235000010445 lecithin Nutrition 0.000 claims abstract description 4
229940067606 lecithin Drugs 0.000 claims abstract description 4
OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims abstract description 3
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims abstract description 3
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims abstract description 3
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims abstract description 3
240000008067 Cucumis sativus Species 0.000 claims abstract description 3
235000010799 Cucumis sativus var sativus Nutrition 0.000 claims abstract description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims abstract description 3
239000004472 Lysine Substances 0.000 claims abstract description 3
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 3
239000005642 Oleic acid Substances 0.000 claims abstract description 3
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims abstract description 3
108010039918 Polylysine Proteins 0.000 claims abstract description 3
BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 claims abstract description 3
PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 claims abstract description 3
DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims abstract description 3
235000020661 alpha-linolenic acid Nutrition 0.000 claims abstract description 3
235000021324 borage oil Nutrition 0.000 claims abstract description 3
229940119217 chamomile extract Drugs 0.000 claims abstract description 3
235000020221 chamomile extract Nutrition 0.000 claims abstract description 3
229940009025 chenodeoxycholate Drugs 0.000 claims abstract description 3
RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 claims abstract description 3
229940009976 deoxycholate Drugs 0.000 claims abstract description 3
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims abstract description 3
229940009662 edetate Drugs 0.000 claims abstract description 3
235000008524 evening primrose extract Nutrition 0.000 claims abstract description 3
239000010475 evening primrose oil Substances 0.000 claims abstract description 3
229940089020 evening primrose oil Drugs 0.000 claims abstract description 3
229960004275 glycolic acid Drugs 0.000 claims abstract description 3
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims abstract description 3
229960004488 linolenic acid Drugs 0.000 claims abstract description 3
KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims abstract description 3
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims abstract description 3
235000021313 oleic acid Nutrition 0.000 claims abstract description 3
229920000656 polylysine Polymers 0.000 claims abstract description 3
229920000056 polyoxyethylene ether Polymers 0.000 claims abstract description 3
229960001860 salicylate Drugs 0.000 claims abstract description 3
PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 claims abstract description 3
229940117972 triolein Drugs 0.000 claims abstract description 3
RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 claims abstract 2
229920001363 Polidocanol Polymers 0.000 claims abstract 2
RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 claims abstract 2
229940074096 monoolein Drugs 0.000 claims abstract 2
229960002969 oleic acid Drugs 0.000 claims abstract 2
229960002226 polidocanol Drugs 0.000 claims abstract 2
208000013016 Hypoglycemia Diseases 0.000 claims description 27
230000002218 hypoglycaemic effect Effects 0.000 claims description 26
239000004615 ingredient Substances 0.000 claims description 11
239000004479 aerosol dispenser Substances 0.000 claims description 10
239000000796 flavoring agent Substances 0.000 claims description 10
235000000346 sugar Nutrition 0.000 claims description 9
229940112822 chewing gum Drugs 0.000 claims description 8
235000015218 chewing gum Nutrition 0.000 claims description 8
OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 claims description 8
239000003755 preservative agent Substances 0.000 claims description 7
239000007921 spray Substances 0.000 claims description 7
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 5
210000005178 buccal mucosa Anatomy 0.000 claims description 5
239000003795 chemical substances by application Substances 0.000 claims description 5
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 5
235000010234 sodium benzoate Nutrition 0.000 claims description 5
239000004299 sodium benzoate Substances 0.000 claims description 5
235000019333 sodium laurylsulphate Nutrition 0.000 claims description 5
235000013355 food flavoring agent Nutrition 0.000 claims description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
229920000053 polysorbate 80 Polymers 0.000 claims description 4
230000002335 preservative effect Effects 0.000 claims description 4
239000003125 aqueous solvent Substances 0.000 claims description 3
239000002585 base Substances 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 3
238000005507 spraying Methods 0.000 claims description 3
239000004150 EU approved colour Substances 0.000 claims description 2
239000004310 lactic acid Substances 0.000 claims description 2
235000014655 lactic acid Nutrition 0.000 claims description 2
229960000448 lactic acid Drugs 0.000 claims description 2
229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 claims description 2
239000003826 tablet Substances 0.000 description 35
230000000694 effects Effects 0.000 description 22
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 16
239000000902 placebo Substances 0.000 description 16
229940068196 placebo Drugs 0.000 description 16
210000004379 membrane Anatomy 0.000 description 11
239000012528 membrane Substances 0.000 description 11
210000000214 mouth Anatomy 0.000 description 11
239000007788 liquid Substances 0.000 description 10
102000004877 Insulin Human genes 0.000 description 9
108090001061 Insulin Proteins 0.000 description 9
239000000243 solution Substances 0.000 description 9
229940125396 insulin Drugs 0.000 description 8
208000024891 symptom Diseases 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
208000001072 type 2 diabetes mellitus Diseases 0.000 description 7
235000020925 non fasting Nutrition 0.000 description 6
239000008213 purified water Substances 0.000 description 6
235000019634 flavors Nutrition 0.000 description 5
239000000693 micelle Substances 0.000 description 5
238000011282 treatment Methods 0.000 description 5
239000000443 aerosol Substances 0.000 description 4
230000037406 food intake Effects 0.000 description 4
239000007951 isotonicity adjuster Substances 0.000 description 4
238000005259 measurement Methods 0.000 description 4
238000002156 mixing Methods 0.000 description 4
210000003254 palate Anatomy 0.000 description 4
238000010561 standard procedure Methods 0.000 description 4
230000009747 swallowing Effects 0.000 description 4
206010010904 Convulsion Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
230000037396 body weight Effects 0.000 description 3
239000003814 drug Substances 0.000 description 3
230000002708 enhancing effect Effects 0.000 description 3
238000009472 formulation Methods 0.000 description 3
230000006870 function Effects 0.000 description 3
150000002989 phenols Chemical class 0.000 description 3
238000012360 testing method Methods 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
206010010071 Coma Diseases 0.000 description 2
206010013887 Dysarthria Diseases 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
208000003443 Unconsciousness Diseases 0.000 description 2
150000001340 alkali metals Chemical class 0.000 description 2
239000004599 antimicrobial Substances 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000007910 chewable tablet Substances 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000001816 cooling Methods 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
229940061607 dibasic sodium phosphate Drugs 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
208000002173 dizziness Diseases 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000012535 impurity Substances 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
238000002483 medication Methods 0.000 description 2
210000004877 mucosa Anatomy 0.000 description 2
239000007968 orange flavor Substances 0.000 description 2
230000004044 response Effects 0.000 description 2
208000026473 slurred speech Diseases 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000006068 taste-masking agent Substances 0.000 description 2
238000012549 training Methods 0.000 description 2
239000002691 unilamellar liposome Substances 0.000 description 2
WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
241000167854 Bourreria succulenta Species 0.000 description 1
235000004936 Bromus mango Nutrition 0.000 description 1
101100002344 Caenorhabditis elegans arid-1 gene Proteins 0.000 description 1
244000241235 Citrullus lanatus Species 0.000 description 1
235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 1
206010009696 Clumsiness Diseases 0.000 description 1
206010011703 Cyanosis Diseases 0.000 description 1
208000012661 Dyskinesia Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
206010016338 Feeling jittery Diseases 0.000 description 1
235000016623 Fragaria vesca Nutrition 0.000 description 1
240000009088 Fragaria x ananassa Species 0.000 description 1
235000011363 Fragaria x ananassa Nutrition 0.000 description 1
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
206010021113 Hypothermia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
206010024264 Lethargy Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
240000007228 Mangifera indica Species 0.000 description 1
235000014826 Mangifera indica Nutrition 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
240000008790 Musa x paradisiaca Species 0.000 description 1
235000018290 Musa x paradisiaca Nutrition 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010029216 Nervousness Diseases 0.000 description 1
206010029412 Nightmare Diseases 0.000 description 1
206010033546 Pallor Diseases 0.000 description 1
244000294611 Punica granatum Species 0.000 description 1
235000014360 Punica granatum Nutrition 0.000 description 1
240000007651 Rubus glaucus Species 0.000 description 1
235000011034 Rubus glaucus Nutrition 0.000 description 1
235000009122 Rubus idaeus Nutrition 0.000 description 1
208000032140 Sleepiness Diseases 0.000 description 1
229920002385 Sodium hyaluronate Polymers 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
235000009184 Spondias indica Nutrition 0.000 description 1
229940100389 Sulfonylurea Drugs 0.000 description 1
244000299461 Theobroma cacao Species 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
235000009499 Vanilla fragrans Nutrition 0.000 description 1
244000263375 Vanilla tahitensis Species 0.000 description 1
235000012036 Vanilla tahitensis Nutrition 0.000 description 1
235000009754 Vitis X bourquina Nutrition 0.000 description 1
235000012333 Vitis X labruscana Nutrition 0.000 description 1
240000006365 Vitis vinifera Species 0.000 description 1
235000014787 Vitis vinifera Nutrition 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
150000005215 alkyl ethers Chemical class 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
208000008784 apnea Diseases 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000003613 bile acid Substances 0.000 description 1
239000003833 bile salt Substances 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
235000019693 cherries Nutrition 0.000 description 1
235000019219 chocolate Nutrition 0.000 description 1
238000004040 coloring Methods 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229940029980 drug used in diabetes Drugs 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
230000003090 exacerbative effect Effects 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
235000002864 food coloring agent Nutrition 0.000 description 1
235000015203 fruit juice Nutrition 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
235000012907 honey Nutrition 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
235000003642 hunger Nutrition 0.000 description 1
229940014041 hyaluronate Drugs 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000002631 hypothermal effect Effects 0.000 description 1
208000013433 lightheadedness Diseases 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
229950004994 meglitinide Drugs 0.000 description 1
239000001525 mentha piperita l. herb oil Substances 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
239000003595 mist Substances 0.000 description 1
208000035824 paresthesia Diseases 0.000 description 1
235000019477 peppermint oil Nutrition 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
208000026438 poor feeding Diseases 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000037321 sleepiness Effects 0.000 description 1
235000011888 snacks Nutrition 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229940010747 sodium hyaluronate Drugs 0.000 description 1
YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000003867 tiredness Effects 0.000 description 1
208000016255 tiredness Diseases 0.000 description 1

Landscapes

Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NZ55305807A 2006-10-06 2007-02-07 Composition and method for raising blood glucose level NZ553058A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA002562821A CA2562821A1 (en)	2006-10-06	2006-10-06	Composition and method for raising blood glucose level

Publications (1)

Publication Number	Publication Date
NZ553058A true NZ553058A (en)	2008-11-28

Family

ID=39399279

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NZ55305807A NZ553058A (en)	2006-10-06	2007-02-07	Composition and method for raising blood glucose level

Country Status (5)

Country	Link
AU (1)	AU2007200571A1 (ru)
BR (1)	BRPI0702158A (ru)
MX (1)	MX2007006203A (ru)
NZ (1)	NZ553058A (ru)
RU (1)	RU2389493C2 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10016370B2 (en) *	2011-07-14	2018-07-10	Able Cerebral, Llc	Composition, device and method for delayed and sustained release of brain energy molecules
RU2634271C1 (ru) *	2016-05-16	2017-10-24	Александр Ливиевич Ураков	Средство для повышения физической выносливости

2007
- 2007-02-07 NZ NZ55305807A patent/NZ553058A/en not_active IP Right Cessation
- 2007-02-09 AU AU2007200571A patent/AU2007200571A1/en not_active Abandoned
- 2007-02-28 BR BRPI0702158 patent/BRPI0702158A/pt not_active IP Right Cessation
- 2007-05-07 RU RU2007117018/15A patent/RU2389493C2/ru not_active IP Right Cessation
- 2007-05-23 MX MX2007006203A patent/MX2007006203A/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
MX2007006203A (es)	2009-02-16
RU2007117018A (ru)	2008-11-20
RU2389493C2 (ru)	2010-05-20
BRPI0702158A (pt)	2008-05-27
AU2007200571A1 (en)	2008-04-24

Publication	Publication Date	Title
US10806709B2 (en)	2020-10-20	Intranasal formulation of epinephrine for the treatment of anaphylaxis
US6432383B1 (en)	2002-08-13	Method for administering insulin
US6017545A (en)	2000-01-25	Mixed micellar delivery system and method of preparation
US20220304980A1 (en)	2022-09-29	Metered dosing compositions and methods of use of psychedelic compounds
WO2020051122A2 (en)	2020-03-12	Cannabinoid, menthol and caffeine dissolvable film compositions, devices and methods
BR112020014596A2 (pt)	2020-12-08	Formulações, composições e métodos farmacêuticos de peptídeo yy
JP2000510841A (ja)	2000-08-22	口への投与のためのリポソーム処方物での生物学的活性物質の送達
CN102639131A (zh)	2012-08-15	舌下右美托咪定组合物及其使用方法
AU2007298814A1 (en)	2008-03-27	Galenic form for the trans-mucosal delivery of active ingredients
US11185526B2 (en)	2021-11-30	Cannabinoid, menthol and caffeine dissolvable film compositions, devices and methods
US20020048551A1 (en)	2002-04-25	Delivery of biologically active material in a liposomal formulation for administration into the mouth
AU685741B2 (en)	1998-01-29	Sprayable analgesic composition and method of use
US20220008331A1 (en)	2022-01-13	Pharmaceutical compositions comprising flurbiprofen
NZ560990A (en)	2009-02-28	Compositions for oral transmucosal delivery of metformin
US20070077258A1 (en)	2007-04-05	ADMINISTRATION OF GLUTATHIONE (REDUCED) VIA INTRAVENOUS OR ENCAPSULATED IN LIPOSOME FOR THE AMELIORATION OF TNF-alpha EFFECTS AND FLU-LIKE VIRAL SYMPTOMS AND TREATMENT AND PREVENTION OF VIRUS
NZ553058A (en)	2008-11-28	Composition and method for raising blood glucose level
US20190125660A1 (en)	2019-05-02	Orally dissolving mucoadhesive films utilizing menthol and l-arginine to enhance the bioavailability of cannabinoids
US20080085331A1 (en)	2008-04-10	Composition and method for raising blood glucose level
RU2282447C2 (ru)	2006-08-27	Никотинсодержащая фармацевтическая композиция и ее применение
CN101983052B (zh)	2013-03-20	一种通过跨口腔粘膜途径进行曲坦类药物给药的药物制剂
CA2562821A1 (en)	2008-04-06	Composition and method for raising blood glucose level
Makwana et al.	2011	Chewing gum: A modern approach to oral mucosal drug delivery
JP2969532B2 (ja)	1999-11-02	ビタミン−ミネラル組成物
WO2021177941A1 (en)	2021-09-10	Cannabinoid, menthol and caffeine dissolvable film compositions, devices and methods

Legal Events

Date	Code	Title	Description
2011-01-28	RENW	Renewal (renewal fees accepted)
2014-08-29	LAPS	Patent lapsed